OBJECTIVES: A low folate/high homocysteine phenotype is associated with several pathologies, including spina bifida and cardiovascular disease. Folate and total homocysteine (tHcy) measurements are used clinically to assess risk and the need for folic acid supplementation and in research to investigate the metabolic basis of disease. Red blood cell (RBC) folate, the best indicator of long-term folate status, is usually measured as "total" folate. However, different folate derivatives support distinct biochemical functions, suggesting a need to develop more precise methods. This study was designed to evaluate a method based on stable isotope dilution liquid chromatography-multiple reaction monitoring/mass spectrometry (LC-MRM/MS). DESIGN AND METHODS: We used LC-MRM/MS to quantify the RBC folate derivatives 5-methyltetrahydrofolate (5-CH(3)-THF), tetrahydrofolate (THF), and 5,10-methenyltetrahydrofolate (5,10-methenylTHF) in pre-menopausal women. The concentration of each folate derivative was assessed for utility in predicting tHcy levels, and compared to folate and tHcy measurements derived by routine clinical laboratory methods. RESULTS: LC-MRM/MS was qualitatively and quantitatively superior to routine clinical laboratory methods for determining folate and tHcy concentrations. RBC 5-CH(3)-THF had a reciprocal relationship with tHcy (p=0.0003), whereas RBC THF and RBC 5,10-methenylTHF had direct relationships (p=0.01, 0.04 respectively). In combination, these three variables accounted for 42% of the variation in tHcy. CONCLUSIONS: Robust methods for measuring RBC 5-CH(3)-THF would improve the utility of folate/homocysteine phenotyping in patient management. The use of LC-MRM/MS would allow studies of hyperhomocysteinemia and diseases associated with a low folate/high homocysteine phenotype to be performed with less measurement error and greater statistical power to generate data with the potential to elucidate the etiologic mechanisms of complex diseases and traits.
OBJECTIVES: A low folate/high homocysteine phenotype is associated with several pathologies, including spina bifida and cardiovascular disease. Folate and total homocysteine (tHcy) measurements are used clinically to assess risk and the need for folic acid supplementation and in research to investigate the metabolic basis of disease. Red blood cell (RBC) folate, the best indicator of long-term folate status, is usually measured as "total" folate. However, different folate derivatives support distinct biochemical functions, suggesting a need to develop more precise methods. This study was designed to evaluate a method based on stable isotope dilution liquid chromatography-multiple reaction monitoring/mass spectrometry (LC-MRM/MS). DESIGN AND METHODS: We used LC-MRM/MS to quantify the RBC folate derivatives 5-methyltetrahydrofolate (5-CH(3)-THF), tetrahydrofolate (THF), and 5,10-methenyltetrahydrofolate (5,10-methenylTHF) in pre-menopausal women. The concentration of each folate derivative was assessed for utility in predicting tHcy levels, and compared to folate and tHcy measurements derived by routine clinical laboratory methods. RESULTS: LC-MRM/MS was qualitatively and quantitatively superior to routine clinical laboratory methods for determining folate and tHcy concentrations. RBC 5-CH(3)-THF had a reciprocal relationship with tHcy (p=0.0003), whereas RBC THF and RBC 5,10-methenylTHF had direct relationships (p=0.01, 0.04 respectively). In combination, these three variables accounted for 42% of the variation in tHcy. CONCLUSIONS: Robust methods for measuring RBC 5-CH(3)-THF would improve the utility of folate/homocysteine phenotyping in patient management. The use of LC-MRM/MS would allow studies of hyperhomocysteinemia and diseases associated with a low folate/high homocysteine phenotype to be performed with less measurement error and greater statistical power to generate data with the potential to elucidate the etiologic mechanisms of complex diseases and traits.
Authors: R J Berry; Z Li; J D Erickson; S Li; C A Moore; H Wang; J Mulinare; P Zhao; L Y Wong; J Gindler; S X Hong; A Correa Journal: N Engl J Med Date: 1999-11-11 Impact factor: 91.245
Authors: Bernard F Cole; John A Baron; Robert S Sandler; Robert W Haile; Dennis J Ahnen; Robert S Bresalier; Gail McKeown-Eyssen; Robert W Summers; Richard I Rothstein; Carol A Burke; Dale C Snover; Timothy R Church; John I Allen; Douglas J Robertson; Gerald J Beck; John H Bond; Tim Byers; Jack S Mandel; Leila A Mott; Loretta H Pearson; Elizabeth L Barry; Judy R Rees; Norman Marcon; Fred Saibil; Per Magne Ueland; E Robert Greenberg Journal: JAMA Date: 2007-06-06 Impact factor: 56.272
Authors: Yuehua Huang; Stefanie Khartulyari; Megan E Morales; Anna Stanislawska-Sachadyn; Joan M Von Feldt; Alexander S Whitehead; Ian A Blair Journal: Rapid Commun Mass Spectrom Date: 2008-08 Impact factor: 2.419
Authors: Stephen J Bagley; Steven Vitale; Suhong Zhang; Charu Aggarwal; Tracey L Evans; Evan W Alley; Roger B Cohen; Corey J Langer; Ian A Blair; Anil Vachani; Alexander S Whitehead Journal: Clin Lung Cancer Date: 2016-10-26 Impact factor: 4.785
Authors: Carolyn M Summers; Andrea L Hammons; Jasbir Arora; Suhong Zhang; Jeanine Jochems; Ian A Blair; Alexander S Whitehead Journal: Eur J Pharmacol Date: 2014-03-18 Impact factor: 4.432